Nebenwirkungen · Spectrila
Spectrila 10,000 U powder for concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 8
HOS-128274 · Präparat HOS-096541
In addition, treatment with asparaginase can result in disturbances in organ systems which exhibit a high level of protein synthesis. Decreased protein synthesis can predominantly lead to liver impairment, acute pancreatitis, decreased insulin production with hyperglycaemia, decreased production of clotting factors (especially fibrinogen and antithrombin III) leading to coagulation disorders (thrombosis, bleeding), and decreased production of lipoproteins resulting in hypertriglyceridaemia.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-19T12:00:00Z · SHA-256 92834041c829ec5e3939ce6e53a59cbb395dd50a747f887333911f0d0075973f · Passage 1f983332742d2c592ba6ac9e618bb15f838a326c998c3523b129913245f75550 · Zeichen 273–768 im Abschnitt